Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

Summary

This study is a Phase 1/2, randomized, observer-blind, active and placebo-controlled, multi-center study to be conducted in approximately 2400 adults 60 years of age and older. The aim of the study is to evaluate the immunogenicity and safety of an RSV+HMPV vaccine candidate for the prevention of RSV and HMPV disease among adults 60 years of age and older. While there are 3 FDA approved/licensed RSV vaccines currently available to the public, no vaccine is available for the prevention of HMPV in older adults.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Respiratory Syncytial Virus Immunization
• Human Metapneumovirus Immunization
• Healthy Volunteers

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

60 years and older

Sex

All

Healthy volunteers

Accepted

Sponsor

Sanofi

Last updated on ClinicalTrials.gov

October 14, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites